Key clinical point: When administered prophylactically, propranolol, topiramate, flunarizine, and cyproheptadine are effective at improving the health-related quality of life in pediatric patients with migraine.
Main finding: The before vs. after mean Pediatric Migraine Disability Assessment scores showed significant improvement with prophylactic topiramate (11.33 ± 13.82 vs. 33.50 ± 13.97), propranolol (12.58 ± 15.67 vs. 30.16 ± 22.97), cyproheptadine (17.00 ± 17.43 vs. 27.33 ± 19.22), or flunarizine (17.50 ± 20.14 vs. 29.89 ± 21.53; all P < .001).
Study details: The data are derived from a retrospective review study including 186 pediatric patients (aged 6 to 18 years) with migraine who were being treated prophylactically for at least 6 months with either topiramate (n = 30), cyproheptadine (n = 45), propranolol (n = 55), or flunarizine (n = 56).
Disclosures: The authors did not receive any financial aid for the study. No conflicts of interest were reported.
Source: Tekin H et al. Pediatr Int. 2021 (Dec 14). Doi: 10.1111/ped.15094.